申请人:MOCHIDA PHARMACEUTICAL CO., LTD.
公开号:EP1048666A1
公开(公告)日:2000-11-02
Novel fused tetracyclic heterocyclic compounds having a potent and highly selective effect of inhibiting cyclic GMP phosphodiesterase (cGMP-PDE) and a high safety; a process for producing the same; drugs characterized by containing at least one of these compounds as the active ingredient, in particular, preventives and/or remedies for pulmonary hypertension, ischemic heart diseases, erectile insufficiency, female sexual dysfunction or diseases against which cGMP-PDE inhibitory effects are efficacious and intermediates useful in producing the above compounds.
新型融合四环杂环化合物,具有抑制环 GMP 磷酸二酯酶(cGMP-PDE)的强效和高选择性作用,且安全性高;其生产工艺;以含有至少一种上述化合物作为活性成分为特征的药物,特别是肺动脉高压、缺血性心脏病、勃起功能障碍、女性性功能障碍或 cGMP-PDE 抑制作用有效的疾病的预防和/或治疗药物,以及用于生产上述化合物的中间体。